<DOC>
	<DOCNO>NCT02095717</DOCNO>
	<brief_summary>Multicenter randomize phase II study , double-blind , compare Taxotere plus curcumin versus Taxotere plus placebo combination first-line treatment prostate cancer metastatic castration resistant . Assess time progression ( time progression ) metastatic disease ( first day treatment trial ) .</brief_summary>
	<brief_title>Multicenter Study Comparing Taxotere Plus Curcumin Versus Taxotere Plus Placebo Combination First-line Treatment Prostate Cancer Metastatic Castration Resistant ( CURTAXEL )</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Curcumin</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>Patient old 18 year . Performance status â‰¤ 2 accord WHO criterion . Life expectancy &gt; 3 month . Patient hormonal blockade base surgical castration orchiectomy pulpectomy , medical agonist antagonist LHRH associate antiandrogens treatment block fraction nongonadal testosterone , result testosterone &lt; 0.5 ng / mL . Patient adenocarcinoma prostate histologically proven metastatic castrationresistant stage , define : objective progression least one measurable tumor target / assessable RECIST , / increase PSA ( `` rise PSA '' ) . Satisfactory biological function ( renal , hepatic hematologic ) Patient sign consent participation enter study . Affiliation social security scheme ( beneficiary plan ) term law 9 August 2004 . Age &lt; 18 year . Performance status &gt; 2 accord WHO criterion . Patient deprive liberty guardianship , patient ( ) condition ( ) psychological , family , social geographic may interfere proper conduct study . Diagnosis second malignancy past 5 year , exception basal cell skin cancer consider cure . Patient brain metastasis initial assessment . Patient another pathology deem incompatible inclusion protocol . Laboratory test inadequate . History malabsorption syndrome extensive resection upper digestive tract . Uncontrolled intercurrent infection . Pathology autoimmune / chronic active inflammation . peripheral neuropathy grade 2 accord criterion National Cancer Institute Common Terminology Criteria Adverse Events ( NCICTCAE , version 4.0 ) . History allergy polysorbate 80 . Treatment nonsteroidal antiinflammatory / cyclooxygenase2 date within three week . Concomitant drug test participation another clinical trial within &lt; 30 day treatment . Regular Taking dietary supplement .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>